Mizuho Securities Sticks to Its Buy Rating for Viewray

By Jason Carr

In a report released yesterday, Difei Yang from Mizuho Securities reiterated a Buy rating on Viewray (NASDAQ: VRAY), with a price target of $12. The company’s shares opened today at $6.19.

According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.4% and a 50.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Fennec Pharmaceuticals Inc, and Spectrum Pharmaceuticals.

Viewray has an analyst consensus of Strong Buy, with a price target consensus of $9.50.

Based on Viewray’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $698K and GAAP net loss of $8.35 million. In comparison, last year the company earned revenue of $357K and had a GAAP net loss of $14.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.